To validate the expression of the ELF3 in ovarian cancer cells, we performed immunolocalization of ELF3 in 22 serous borderline ovarian tumor (SBOT), 23 low-grade serous ovarian cancer (LGSC), and 127 high-grade serous ovarian carcinoma (HGSC) tissue samples (Figure 1B). This evidence concerns the gene ELF3 and ovarian carcinoma.